Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CDK4/6 Inhibitors Impair Recovery from Cytotoxic Chemotherapy in Pancreatic Adenocarcinoma.

Cancer cell - 16 Mar 2020

Salvador-Barbero Beatriz, Álvarez-Fernández Mónica, Zapatero-Solana Elisabet, El Bakkali Aicha, Menéndez María Del Camino, López-Casas Pedro P, Di Domenico Tomas, Xie Tao, VanArsdale Todd, Shields David J, Hidalgo Manuel, Malumbres Marcos

Abstract excerpt

Inhibition of the cell-cycle kinases CDK4 and CDK6 is now part of the standard treatment in advanced breast cancer. CDK4/6 inhibitors, however, are not expected to cooperate with DNA-damaging or antimitotic chemotherapies as the former prevent cell-cycle entry, thus interfering with S-phase- or mitosis-targeting agents. Here, we report that sequential administration of CDK4/6 inhibitors after taxanes cooperates...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Albumins
Share to Carcinoma, Pancreatic Ductal

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyclin-Dependent Kinase 4

Share to Cyclin-Dependent Kinase 6

Share to Drug Administration Schedule

Share to Homologous Recombination

Share to Neoplasms, Experimental

Share to Paclitaxel

Source

Identifiers

PMID: 32109375
DOI: 10.1016/j.ccell.2020.01.007

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CDK4/6 Inhibitors Impair Recovery from Cytotoxic Chemotherapy in Pancreatic Adenocarcinoma.PMID 32109375Read ↗

CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancerSemantic proximity Read ↗

Differential Regulation of Cancer Progression by CDK4/6 Plays a Central Role in DNA Replication and Repair PathwaysSemantic proximity Read ↗

Targeting CDK4/6 in patients with cancerSemantic proximity Read ↗

CDK4 and CDK6 kinases: From basic science to cancer therapySemantic proximity Read ↗

The regulatory role of CDK4/6 inhibitors in tumor immunity and the potential value of tumor immunotherapy (Review)Semantic proximity Read ↗

Molecular Pathways: Targeting the Cyclin D–CDK4/6 Axis for Cancer TreatmentSemantic proximity Read ↗

Modification of the DNA Damage Response by Therapeutic CDK4/6 InhibitionSemantic proximity Read ↗

Clinical CDK4/6 inhibitors induce selective and immediate dissociation of p21 from cyclin D-CDK4 to inhibit CDK2Semantic proximity Read ↗

Selective impact of CDK4/6 suppression on patient-derived models of pancreatic cancerSemantic proximity Read ↗

INK4 Tumor Suppressor Proteins Mediate Resistance to CDK4/6 Kinase InhibitorsSemantic proximity Read ↗

CDK6 Antagonizes p53-Induced Responses during Tumorigenesis.Semantic proximity Read ↗

Cdk4 and Cdk6 cooperate in counteracting the INK4 family of inhibitors during murine leukemogenesis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.